[Alpha Biz= Kim Jisun] SEOUL, November 19 — CHA Bio Group announced it will deepen strategic cooperation in global digital healthcare through an equity swap with Kakao.
CHA Biotech disclosed that it has approved a KRW 30 billion third-party allotment capital increase to Kakao. In addition, CHA Biotech subsidiaries CHA CARES and CHA AI Healthcare will invest KRW 80 billion—via share purchases and participation in a capital increase—to secure management control of Kakao Healthcare, a Kakao subsidiary.
Kakao Healthcare is also set to raise KRW 50 billion from external investors by Q1 2026. Upon completion, the ownership structure will be:
CHA CARES & CHA AI Healthcare: 43.08%
Kakao: 29.99%
External investors: 26.93%
Leveraging Kakao Healthcare’s digital platforms—such as the mobile health management services PASTA, HRS, and HeyCon, as well as its medical data and hospital concierge service CareChat—CHA Bio Group plans to expand digital healthcare offerings within its global medical network.
With Kakao Healthcare’s IT capabilities integrated, CHA Bio Group aims to strengthen its position as a leading smart healthcare provider, advancing connected healthcare across living spaces, communities, and medical institutions, while also expanding senior-focused healthcare services.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
